Please Wait
Applying Filters...
menu
    • menu
    Evonik

    Virtual Booth

    Contact Supplier

    Sharp is a global leader in pharmaceutical packaging and clinical trial supply services.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-04-21

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-04-14

    Virtual Booth

    Contact Supplier

    Menu

    Zyprexa

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    $ API Ref.Price (USD/KG) : 920Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    J&J & Lilly Concealed Breast Cancer Risks in Antipsychotics Drug
    J&J & Lilly Concealed Breast Cancer Risks in Antipsychotics Drug

    24 Apr 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/jj-and-eli-lilly-concealed-breast-cancer-risks-in-blockbuster-antipsychotics-for-decades-wisner-baum-lawsuit-alleges-302436429.html

    PR NEWSWIRE
    24 Apr 2025
    Share Share
    Teva's Schizophrenia Portfolio Enhanced by Ph 3 Trial Results
    Teva's Schizophrenia Portfolio Enhanced by Ph 3 Trial Results

    31 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/31/3052605/0/en/New-Data-Strengthens-Teva-s-Schizophrenia-Portfolio-Including-Phase-3-SOLARIS-Trial-Survey-Results-Demonstrating-Patient-and-Healthcare-Professional-Satisfaction-with-TEV-749-olanz.html

    GLOBENEWSWIRE
    31 Mar 2025
    Share Share
    Teva Completes Phase 3 Trial For Olanzapine LAI In Schizophrenia
    Teva Completes Phase 3 Trial For Olanzapine LAI In Schizophrenia

    10 Feb 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250209967526/en

    BUSINESSWIRE
    10 Feb 2025
    Share Share
    Sunshine Biopharma launches Olanzapine and Olanzapine ODT
    Sunshine Biopharma launches Olanzapine and Olanzapine ODT

    22 Jan 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/news/sunshine-biopharma-launches-olanzapine-and-olanzapine-odt-16694

    INDPHARMAPOST
    22 Jan 2025
    Share Share
    Enforcement Report - Week of December 25, 2024
    Enforcement Report - Week of December 25, 2024

    25 Dec 2024

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-december-25-2024-24704.pdf

    FDA
    25 Dec 2024
    Share Share
    Teva Presents Schizophrenia Research, Phase 3 SOLARIS Trial Results
    Teva Presents Schizophrenia Research, Phase 3 SOLARIS Trial Results

    01 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/01/2973519/0/en/Teva-Presents-Latest-Schizophrenia-Treatment-Research-Including-Phase-3-SOLARIS-Trial-Results-Demonstrating-Improvements-in-Social-Functioning-and-Quality-of-Life-in-Adults-Receivi.html

    GLOBENEWSWIRE
    01 Nov 2024
    Share Share